Less than a tenth of people eligible to benefit from obesity jabs like Wegovy have access to them, warns the World Health Organization as it publishes its initial guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging increased and just availability to GLP-1 medication.
According to forecasts, over two billion could be obese by 2030 if no action is taken.
"Our latest guidelines recognises that obesity is a long-term condition that can be treated with thorough and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant barriers to universal availability to the jabs that can aid individuals in losing substantial weight, notes the agency.
Weight-Loss Drug Shortage
Despite the present most favorable outlook, the manufacturing of such drugs could only cover around 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation calls on countries and companies to widen access, by strategies like voluntary licensing.
A patent on semaglutide – the primary ingredient of a leading brand – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Jabs Work
GLP-1 drugs replicate a biological compound to delay gastric emptying, suppress the appetite and boost the sense of being full so individuals reduce food intake.
Individuals commonly start to lose weight after several weeks of commencing the regular doses.
Studies suggests users may see weight return a year later of discontinuing the medication, as their typical appetite return.
To be carrying excess weight elevates your chance for contracting health problems, including type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight impacts individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
